10q is out. Note that outstanding shares increased less than 10M shares in Q3 demonstrating Leo’s continual efforts to keep dilution at a minimal as IPIX advance their science. Detailed Outstanding share count went from 202,631,923 to 212,369,124 between 6/30/19 and 9/30/19 or 9,737,201 shares total.
IPIX received $400k in upfront cash on the Alfasigma IBD partnership which is in the range I was expecting. When IPIX announced the Alfasigma deal and did not follow up immediately with a B-OM phase 3 announcement that was a "tell" that they did not have enough resources to pay for a B-OM phase 3. The Alfasigma deal IMO is strategic in that some development and science advancement costs have been offloaded to Alfasigma and the deal further validates the Brilacidin science in addition to FDA validation. The B-IBD foam/enema market is a relatively small share of the overall IBD market and the partnership deal terms and conditions parallel this. My above sticky was written at a point that I was expecting the Term Sheet to produce a larger partnership but I now believe the 2nd partnership will be the significant one. A Brilacidin pill that will target specific areas to address the Colitis and Crohn's disease markets represent the largest Brilacidin revenue opportunities IMO. I believe the next partnership will be valued based on this enormous market opportunity and have significant upfront dollars which will limit further IPIX SP dilution. The bashers have been trying to set false narratives over what dictates a success/failure based of the dollar amount of upfront payments. I also found it interesting in the 10q that 60% of the OM market opportunity is represented in 500 locations and that a "small sales force" could cover this OM market opportunity. Some investors have indicated in the past that IPIX could take B-OM to market on their own and whether they do or not, the option is certainly possible if the right partnership deal for B-OM does not come along. An example is that an IBD pill partnership deal of significance gets inked in early to mid 2020 but that no B-OM deal had been struck yet. IPIX could decide to take up front monies from a large IBD pill partnership and allocate funds to do the B-OM phase 3 on their own and hire a small sales/manufacture-rep arrangement to sell B-OM where IPIX keeps 90% of revenue vs 12-15% on a license deal. I think having multiple options is always a good thing especially in a negotiation environment. I do not personally believe that any Longs are selling at these ridiculously compressed prices and the ONLY thing the criminals control is the SHORT TERM share price. As the criminals do their best to set new 52 week lows, there are many of us Longs that have been able to add to our positions and lower our average share price. With more shares in strong hands the eventual rise in SP could be significant. I am personally confident in the long term success of IPIX but this has been a major test in patience for all involved.
IPIX received $400k in upfront cash on the Alfasigma IBD partnership which is in the range I was expecting. When IPIX announced the Alfasigma deal and did not follow up immediately with a B-OM phase 3 announcement that was a "tell" that they did not have enough resources to pay for a B-OM phase 3. The Alfasigma deal IMO is strategic in that some development and science advancement costs have been offloaded to Alfasigma and the deal further validates the Brilacidin science in addition to FDA validation. The B-IBD foam/enema market is a relatively small share of the overall IBD market and the partnership deal terms and conditions parallel this. My above sticky was written at a point that I was expecting the Term Sheet to produce a larger partnership but I now believe the 2nd partnership will be the significant one. A Brilacidin pill that will target specific areas to address the Colitis and Crohn's disease markets represent the largest Brilacidin revenue opportunities IMO. I believe the next partnership will be valued based on this enormous market opportunity and have significant upfront dollars which will limit further IPIX SP dilution. The bashers have been trying to set false narratives over what dictates a success/failure based of the dollar amount of upfront payments. I also found it interesting in the 10q that 60% of the OM market opportunity is represented in 500 locations and that a "small sales force" could cover this OM market opportunity. Some investors have indicated in the past that IPIX could take B-OM to market on their own and whether they do or not, the option is certainly possible if the right partnership deal for B-OM does not come along. An example is that an IBD pill partnership deal of significance gets inked in early to mid 2020 but that no B-OM deal had been struck yet. IPIX could decide to take up front monies from a large IBD pill partnership and allocate funds to do the B-OM phase 3 on their own and hire a small sales/manufacture-rep arrangement to sell B-OM where IPIX keeps 90% of revenue vs 12-15% on a license deal. I think having multiple options is always a good thing especially in a negotiation environment. I do not personally believe that any Longs are selling at these ridiculously compressed prices and the ONLY thing the criminals control is the SHORT TERM share price. As the criminals do their best to set new 52 week lows, there are many of us Longs that have been able to add to our positions and lower our average share price. With more shares in strong hands the eventual rise in SP could be significant. I am personally confident in the long term success of IPIX but this has been a major test in patience for all involved.
17
1
